Concert Genetic Testing: Hematologic Conditions (non-cancerous)

This policy covers genetic and molecular testing to confirm and guide management of non‑cancerous hematologic conditions — including evaluation of inherited thrombophilias (F5/F2), hemoglobinopathies (HBA/HBA2/HBB), hemophilia A/B (F8/F9), G6PD and VWF analyses when clinically indicated, and prenatal/preconception carrier and diagnostic testing for listed disorders. Coverage is limited to the specific clinical indications listed (e.g., F5/F2 testing only in defined VTE scenarios such as planned anticoagulation discontinuation, cerebral or splanchnic thrombosis, or specified family histories); many variant analyses are investigational and not covered outside those indications, biochemical testing is preferred for G6PD and VWD, and the Concert platform contains the definitive list of covered tests.

"Genetic testing for non-cancerous hematologic conditions to confirm a diagnosis in patients with signs and/or symptoms of a specific hematologic condition."